Second surgery for recurrent glioblastoma: advantages and pitfalls

References

• Crocetti E, Trama A, Stiller C et al.; RARECARE working group. Epidemiology of glial and non-glial brain tumours in Europe. Eur. J. Cancer 48(10), 1532–1542 (2012).
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352(10), 987–996 (2005).
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME, Mason WP et al.; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised Phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10(5), 459–466 (2009).
   PubMed Web of Science ®Google Scholar
• Brandes AA, Tosoni A, Spagnolli F et al. Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. Neuro-oncology 10(3), 361–367 (2008).
   PubMed Web of Science ®Google Scholar
• Wen PY, Macdonald DR, Reardon DA et al. Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology Working Group. J. Clin. Oncol. 28(11), 1963–1972 (2010).
   PubMed Web of Science ®Google Scholar
• DeAngelis LM, Delattre JY, Posner JB. Radiation-induced dementia in patients cured of brain metastases. Neurology 39(6), 789–796 (1989).
   PubMed Web of Science ®Google Scholar
• Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J. Clin. Oncol. 26(13), 2192–2197 (2008).
   PubMed Web of Science ®Google Scholar
• Brandes AA, Franceschi E, Tosoni A et al. O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications. Neuro-oncology 12(3), 283–288 (2010).
   PubMed Web of Science ®Google Scholar
• Felsberg J, Thon N, Eigenbrod S et al.; German Glioma Network. Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. Int. J. Cancer 129(3), 659–670 (2011).
   PubMed Web of Science ®Google Scholar
• Metellus P, Coulibaly B, Nanni I et al. Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort. Cancer 115(20), 4783–4794 (2009).
   PubMed Web of Science ®Google Scholar
• Brandes AA, Vastola F, Monfardini S. Reoperation in recurrent high-grade gliomas: literature review of prognostic factors and outcome. Am. J. Clin. Oncol. 22(4), 387–390 (1999).
   PubMed Web of Science ®Google Scholar
• Ammirati M, Galicich JH, Arbit E, Liao Y. Reoperation in the treatment of recurrent intracranial malignant gliomas. Neurosurgery 21(5), 607–614 (1987).
   PubMed Web of Science ®Google Scholar
• Landy HJ, Feun L, Schwade JG, Snodgrass S, Lu Y, Gutman F. Retreatment of intracranial gliomas. South. Med. J. 87(2), 211–214 (1994).
   Google Scholar
• Keles GE, Anderson B, Berger MS. The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere. Surg. Neurol. 52(4), 371–379 (1999).
   PubMed Web of Science ®Google Scholar
• Pinsker M, Lumenta C. Experiences with reoperation on recurrent glioblastoma multiforme. Zentralbl. Neurochir. 62(2), 43–47 (2001).
   Google Scholar
• Mandl ES, Dirven CM, Buis DR, Postma TJ, Vandertop WP. Repeated surgery for glioblastoma multiforme: only in combination with other salvage therapy. Surg. Neurol. 69(5), 506–509; discussion 509 (2008).
   Google Scholar
• McGirt MJ, Chaichana KL, Gathinji M et al. Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J. Neurosurg. 110(1), 156–162 (2009).
   PubMed Web of Science ®Google Scholar
• Park JK, Hodges T, Arko L et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. J. Clin. Oncol. 28(24), 3838–3843 (2010).
   PubMed Web of Science ®Google Scholar
• Xu T, Chen J, Lu Y. Recurrent glioblastoma: not only surgery. J. Clin. Oncol. 29(4), e102; author reply e103 (2011).
   Google Scholar
• Clarke JL, Ennis MM, Yung WK et al.; North American Brain Tumor Consortium. Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? Neuro-oncology 13(10), 1118–1124 (2011).
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Silbergeld DL. Is graded prognostic assessment an improvement compared with radiation therapy oncology group’s recursive partitioning analysis classification for brain metastases? J. Clin. Oncol. 30(26), 3315–3316; author reply 3316 (2012).
   Google Scholar
• De Bonis P, Fiorentino A, Anile C et al. The impact of repeated surgery and adjuvant therapy on survival for patients with recurrent glioblastoma. Clin. Neurol. Neurosurg. doi:10.1016/j.clineuro.2012.08.030 (2012) (Epub ahead of print).
   Google Scholar
• Carson KA, Grossman SA, Fisher JD, Shaw EG. Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium Phase I and II clinical trials. J. Clin. Oncol. 25(18), 2601–2606 (2007).
   PubMed Web of Science ®Google Scholar
• Gorlia T, Stupp R, Brandes AA et al. New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group Phase I and II clinical trials. Eur. J. Cancer 48(8), 1176–1184 (2012).
   PubMed Web of Science ®Google Scholar
• Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ; ALA-Glioma Study Group. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre Phase III trial. Lancet Oncol. 7(5), 392–401 (2006).
   PubMed Web of Science ®Google Scholar